FDA Approval Expected Monday of Ketamine-derived “Spravato”
TAKE HOME POINTS: SpravatoTM, a form of ketamine, will be FDA approved on Monday for Treatment Resistant Depression and for Major Depression with suicidality. FDA approval will result in insurance coverage for this form of ketamine, for this purpose, which will make it affordable for millions of suffering patients. Although it is...
New Psychology Today article on Ketamine
The current edition of Psychology Today has a (mostly accurate) article about the revolutionary success ketamine has in treating depression and PTSD. We applaud their raising public awareness about the fact that ketamine removes suicidality within hours, and that it works overall in about 70 percent of patients who have not gotten adequate relief from...